What GLP-1 Meds Mean For Mental Health & Addiction
From Modern Metabolic Health with Dr. Lindsay Ogle, MD · 18:18
Show by Lindsay Ogle, MD
Find a therapist at https://www.psychologytoday.com/Crisis line -- call or text 988 for immediate help and supportTobacco quit line -- call 1-800-QUIT-NOWQuickMD for help quiting opioids, including Kratom & 7-OHNational Substance Abuse and Mental Health Services (SAMHSA) GLP-1 medications are changing more than the number on the scale and that raises a big question: what happens when we turn down the brain’s reward signals? We walk through how GLP-1 receptor agonists act in the gut and in the brain, why many people feel satisfied sooner, and why some notice cravings shift in unexpected ways. Because the same reward pathways involved in food motivation can overlap with mood and substance use, this topic sits right at the intersection of obesity medicine, addiction medicine, and mental health care.We also take the headlines seriously. Reports of suicidal thoughts made news as GLP-1s became more widely prescribed, so we look at what the best available evidence says, including a large meta-analysis of randomized controlled trials involving about 108,000 participants that found no overall increase in psychiatric side effects versus placebo. At the same time, we explain the real-world nuance: many trials exclude people with severe or unstable psychiatric illness, and major body and lifestyle changes can be emotionally complex. We talk about anhedonia, the “feeling flat” side effect some patients report, why it might happen, and how dose adjustments or switching medications can help.Then we dig into substance use disorder research, including why alcohol reduction is one of the most common changes people report on GLP-1s, what early signals show for nicotine cravings, and why proven smoking cessation supports still matter. We also discuss a large VA observational study suggesting veterans with type 2 diabetes on GLP-1s had a lower risk of documented substance use disorders compared with those on SGLT2 inhibitors, a promising finding that still needs more research. If you find this kind of evidence-based metabolic health guidance helpful, subscribe, share the show with a friend, and leave a review so more people can find it. What questions do you want us to tackle next?👩🏼⚕️ Live in Missouri? Want to be my patient?Telehealth clinic: https://missourimetabolichealth.com🥑 Have questions you want answered on the podcast? Email [email protected]✨Freebies✨GLP-1 GuideZepbound Kwikpen ChartObesity Management MedicationsProteinFiberHow To Prevent DiabetesHealthy Habits WorkbookPreventative Health Checklist🤗 Socials:Instagram: https://www.instagram.com/dr.lindsayogle/TikTok: https://www.tiktok.com/@dr..lindsay.ogle?_t=8prC4VUQZ5i&_r=1YouTube: https://www.youtube.com/channel/UCMV0X6U0JLZgRMiNwGtmpegProCare Supplements (10% off CODE: Metaboli...
More episodes of Modern Metabolic Health with Dr. Lindsay Ogle, MD
More episodes
- Stress Management That Actually Works With Ra Suh, LCSW
- Slow Burn Obesity Phenotype
- New FDA Trials for GLP-1 Coverage
- Emotional Hunger Obesity Phenotype
- Still Hungry On A GLP-1? Here Is What You Can Do!
- Hungry Gut Obesity Phenotype
- Binge Eating Disorder Is Treatable And You Are Not Alone
- Hungry Brain Obesity Phenotype
- PMOS Is The New PCOS: Emphasis On Metabolic Health
- Obesity Phenotypes & Why Ozempic May Not Be Right For You
podsearch is a free, independent podcast search engine. Read about podsearch, the privacy policy or contact us.